New Publication from the LMC Endocrinologist Group: The Impact of SGLT2i’s (dapagliflozin) on Mg Levels in People with T2D

New Publication from the LMC Endocrinologist Group: The Impact of SGLT2i’s (dapagliflozin) on Mg Levels in People with T2D

LMC Manna Research is proud to share an article that Dr. Ron Goldenberg had co-authored.

This is a hot area as it turns out that 1 in 7 of our T2D patients are Mg deficient and, in this meta-analysis, 77% of those patients achieved normal Mg levels.  Low Mg levels can impact glycemic control, lipid levels and cardiac function.  Are SGLT2i’s improving HF outcomes partially through correction of Mg levels? Do take a look at the article to learn more about the impact of SGLT2i’s and the health of people with Type 2 Diabetes!

Dapagliflozin and Magnesium Pooled Analysis J Diab Compl 2019 copy